Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV) introduced the development of its aggressive “Go to Market” technique for growth of SofPulse^® medical system distribution via the U.S. Division of Defense (DoD), Veterans Administration (VA) and different federal healthcare services (FHS) contracts.

President and Chief Business Officer of Endonovo’s Medical Division, Ira Weisberg, is overseeing the “Go to Market” technique and is actively partaking in contract talks geared towards increasing gross sales and advertising and marketing efforts for licensing and distribution contracts of SofPulse^® via the federal government channels.

The VA and DoD are answerable for offering healthcare and different providers to members of the navy and veteran populations in the US. Each the VA and DoD have established programs for buying items and providers, which can embody particular necessities for contractors, reminiscent of registered Small Enterprise Administration (SBA) companies or Service-Disabled Veteran-Owned Small Enterprise (SDVOSB) companies.

Weisberg Leads Negotiations.

In making the announcement, Weisberg commented: “We’re actively negotiating with a veteran-owned firm that may present for the introduction of SofPulse^® into the Division of Defense, Veterans Administration and different federal healthcare services. Offering SofPulse^®, an FDA cleared medical system, designed to supply a viable different to opioid ache administration for surgical sufferers to all our DoD and VA physicians, hospitals and sufferers presents a ache administration answer that has proven to supply sufferers with improved post-surgical outcomes.

Weisberg continued: “Endonovo is increasing our mission to turn into a chief provider into the federal provide system and increasing the advantages of SofPulse^®. We’re presently engaged in talks with a world-class authorities and tutorial collaboration to deliver smart ache administration strategies to the navy.”

Story continues

“NewCo” Spin–Off to Focus on SofPulse^®

Endonovo is presently increasing gross sales and advertising and marketing efforts in assist of its “Go to Market” technique with the idea that new administration and gross sales efforts can take the beforehand introduced spin-off, NewCo, targeted on SofPulse^® medical gadgets and IP to generate greater than $100 million in gross sales by2024. The projected timeline for the NewCo to be listed as a NASDAQ firm, will likely be clarified over the primary half of 2023.

In line with Weisberg: “Rising gross sales with established authorities contractors is an environment friendly approach to proceed the commercialization of SofPulse^®. We consider that by including massive authorities contracts to our gross sales and distribution channels via our navy and authorities affected person populations we will attain the $50 million projected pre-money valuation for NewCo post-closing of the medical system belongings from Endonovo.”

VA.gov studies: “The Veterans Well being Administration (VHA) is the biggest built-in well being care system in the US, offering care at 1,298 well being care services, together with 171 VA Medical Facilities and 1,113 outpatient websites of care of various complexity (VHA outpatient clinics) to over 9 million Veterans enrolled within the VA well being care program.”

Americanaddictioncenters.org studies: “The nationwide opioid disaster have an effect on each demographic however none so closely as veterans. In line with Robert Wilkie, the Secretary of Veterans Affairs, veterans are twice as prone to die from an opioid overdose than civilian Individuals. U.S. navy veteran have been closely impacted by the opioid overdose disaster, with drug overdose mortality charges growing by 53% from 2010–2019.”
Supply: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9262363/pdf/IANN_54_2092896.pdf

PAIN MANAGEMENT PROGRAM INTRODUCED

Weisberg continued: “As an vital aspect of our ‘Go to Market’ technique, Endonovo has developed a ‘Ache Enchancment Program’ (PIP) to give attention to navy and veterans’ surgical outcomes. We consider the PIP initiative will pave the best way to enhance the surgical outcomes and scale back opioid use for our lively navy heroes, their households in addition to our veterans. Our Firm is dedicated to bettering the standard of lifetime of our little children in lively navy service in addition to those that have already served. Bringing SofPulse^® non- opioid ache discount advantages to our navy, retired navy veterans and different federal staff is an obligation we don’t take frivolously.”

SofPulse^® is a medical system that’s designed to supply a viable different to opioid ache administration for surgical sufferers. The system makes use of Pulsed Electro-Magnetic Area (PEMF) remedy to scale back ache and edema (swelling) following surgical procedure. PEMF remedy is a non-invasive therapy that makes use of low-frequency electromagnetic fields to stimulate the physique’s pure therapeutic processes and has proven to be a protected and efficient different to opioids for managing ache and decreasing edema following surgical procedure.

Weisberg concluded: “I’m extraordinarily pleased with our Firm in its speedy completion of the PIP initiative to deliver a confirmed drug-free ache administration system to our navy, authorities and veterans affected person populations. Extending the advantages of SofPulse^® into affected person populations which can be severely impacted by the opioid disaster was seen by our Firm as a mission important requirement for the re-launch of SofPulse^® as a holistic drug-free different to opioids for surgical ache administration.”

About Endonovo Therapeutics, Inc.

Endonovo Therapeutics is presently structured into two divisions: Legacy – a commercial-stage developer primarily of noninvasive wearable Electroceuticals^® therapeutic gadgets for ache reduction, common wellness and wound curatives with lots of its merchandise marketed underneath the SofPulse^® model title; and its Construct Up Technique – buying complementary specialty service suppliers within the development business.

Safe Harbor Statement

This press launch comprises info that constitutes forward-looking statements made pursuant to the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. All statements, developments, evaluation, and different info contained on this press launch together with phrases reminiscent of “anticipate”, “consider”, “plan”, “estimate”, “anticipate”, “intend” and different related expressions of opinion, represent forward-looking statements. Any such forward-looking statements contain dangers and uncertainties that would trigger precise outcomes to vary materially from any future outcomes described throughout the forward-looking statements. Danger elements that would contribute to such variations embody these issues extra totally disclosed within the Firm’s studies filed with the Securities and Alternate Fee. The forward-looking info offered herein represents the Firm’s estimates as of the date of the press launch, and subsequent occasions and developments could trigger the Firm’s estimates to alter. The Firm particularly disclaims any obligation to replace the forward-looking info sooner or later. Subsequently, this forward-looking info shouldn’t be relied upon as representing the Firm’s estimates of its future monetary efficiency as of any date subsequent to the date of this press launch.

Investor Relations Contact:
Endonovo Therapeutics, Inc.
Steve Barnes
(800) 701-1223 Ext. 108
sbarnes@endonovo.com
www.endonovo.com

Media Contact:
Gregory A. McAndrews
Greg McAndrews & Associates
(310) 804-7037
greg@gregmcandrews.com